Fidson Healthcare Plc has approved a N3.6 billion dividend for shareholders after posting a record financial performance that made it the first pharmaceutical company in Nigeria to generate more than N100 billion in annual revenue, reinforcing its ambition to become the largest pharmaceutical manufacturer in Sub-Saharan Africa.
At its 27th Annual General Meeting held virtually on July 30, shareholders approved a dividend of N1.50 per 50 kobo ordinary share, rewarding investors after what the company described as a defining year for its business.
The dividend approval follows a year in which Fidson recorded N119.06 billion in revenue for 2025, setting a new benchmark for Nigeria’s pharmaceutical industry at a time when local drug manufacturers are expanding production to reduce the country’s dependence on imported medicines.
Read also: Rotary Club of Ikoyi Metro champions inspiring maternal and child health drive
Speaking at the meeting, Fidelis Ayebae, the founder and chairman of Fidson
This post was originally published on this site.
